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ABSTRACT
According to the sequential metastasis model, aggressive mesenchymal (M) 
metastasis-initiating cells (MICs) are generated by an epithelial-mesenchymal 
transition (EMT) which eventually is reversed by a mesenchymal-epithelial 
transition (MET) and outgrowth of life-threatening epithelial (E) macrometastases. 
Paradoxically, in breast cancer M signatures are linked with more favorable outcomes 
than E signatures, and M cells are often dispensable for metastasis in mouse models. 
Here we present evidence at the cellular and patient level for the cooperation 
metastasis model, according to which E cells are MICs, while M cells merely support 
E cell persistence through cooperation. We tracked the fates of co-cultured E and 
M clones and of fluorescent CDH1-promoter-driven cell lines reporting the E state 
derived from basal breast cancer HMLER cells. Cells were placed in suspension state 
and allowed to reattach and select an EMT cell fate. Flow cytometry, single cell and 
bulk gene expression analyses revealed that only pre-existing E cells generated E 
cells, mixed E/M populations, or stem-like hybrid E/M cells after suspension and that 
complete EMT manifest in M clones and CDH1-negative reporter cells resulted in loss 
of cell plasticity, suggesting full transdifferentiation. Mechanistically, E-M coculture 
experiments supported the persistence of pre-existing E cells where M cells inhibited 
EMT of E cells in a mutual cooperation via direct cell-cell contact. Consistently, M 
signatures were associated with more favorable patient outcomes compared to E 
signatures in breast cancer, specifically in basal breast cancer patients. These findings 
suggest a potential benefit of complete EMT for basal breast cancer patients.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 28), pp: 20018-20033
INTRODUCTION
While most primary breast tumors are successfully 
eliminated by surgery, metastasis remains incurable 
and accounts for the vast majority of patient deaths [1]. 
Metastatic tumors are thought to originate from a small 
population of stem-like cells within the primary tumor, 
termed cancer stem cells (CSCs), which due to their 
capacity of self-renewal and plasticity [2] can initiate 
the metastatic cascade requiring invasion, migration, 
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intravasation, survival of detachment and anoikis 
resistance in the circulation, extravasation and formation of 
epithelial macrometastases. Accordingly, CSC enrichment 
in primary tumors can predict poor patient outcomes 
[3]. The notion of the CSC-concept was soon combined 
with the older idea of EMT, during which epithelial (E) 
carcinoma cells with cobble-stone like morphology 
convert to a fibroblast-like mesenchymal (M) type of 
cell that can complete the initial steps of the metastatic 
cascade. Indeed, in the context of luminal epithelial 
cell lines of mammary gland tissue or tumors, such as 
HMLE, HMLER, and MCF7, the M cell-type has more 
CSC-like properties than the epithelial bulk population 
[4, 5]. However, in the context of basal, mesenchymal 
cell lines, more CSC-like properties were detected in the 
adhesion–dependent E population [6–9]. The concept of 
stemness of an intermediate E/M state can explain context-
dependency and has been supported experimentally at the 
cell population level indicating a mixture and cooperation 
of E and M cells and is manifested at single cell level in 
the existence of a hybrid E/M cell type that co-expresses E 
and M gene signatures in vitro and in vivo [10–15], and has 
been predicted by theoretical models [16]. Consistently, 
co-expression of E and M-specific gene signatures in 
patient tumors, either due to mixture or presence of the 
hybrid cells, predicts poor survival in diverse breast cancer 
subtypes [12]. However, to date the stem-like intermediate 
E/M state remains untargetable due to the absence of 
specific markers, in comparison to the better defined 
differentiated E or differentiated M states, and the cellular 
origin of hybrid E/M cells remains unclear. 
Previously, two competing metastasis models have 
been proposed, where metastases are either caused by (1) 
individual M cells establishing new metastatic tumors 
(as CSCs or MICs) according to the popular sequential 
metastasis model or (2) by E cells acting as MICs with 
cooperating M cells as supporting cells, as proposed by 
the cooperation metastasis model. 
The sequential metastasis model (1) assumes 
that the metastatic process is initiated by an EMT [17], 
generating individual aggressive M cells [18]. Since life-
threatening proliferating macrometastases typically have 
epithelial morphology and are carcinoma, often exhibiting 
features of normal differentiated breast epithelium, it 
has been postulated that for colonization and expansion 
at the new site the individual M cell must reverse to the 
epithelial state in a process referred to as mesenchymal-
to-epithelial-transition (MET) [17, 19, 20]. This process 
implies plasticity of M cells. However, experimental 
validation of complete MET of individual cells in vivo is 
still lacking [21, 22]. In support of MET, or reversibility 
of EMT, we recently demonstrated in vitro that clonal 
M cells from the tumorigenic breast cell line HMLER 
cultured as stem cell enriched mammospheres (MS) could 
undergo partial MET and generated individual hybrid E/M 
cells [12], but their stability remained unclear. However, 
several experimental observations suggest that complete 
EMT is irreversible because sustained and complete EMT 
induction ablates cellular phenotypic plasticity in vitro 
[9, 23–27]. Accordingly, in mice continuous induction of 
EMT decreases incidence of epithelial metastasis [26, 28]. 
Further, in vitro findings show that single cell-derived M 
clones from HMLER cells are not plastic [12, 29]. Finally, 
in vivo cell tracking in mice revealed that EMT and thus M 
cells did not form lung metastases in breast and pancreatic 
cancer [30, 31], further questioning if M cells are MICs. 
Consistent with the observed absence of M 
cell plasticity, the alternative cooperation metastasis 
model (2), originally termed cooperativity theory [32], 
proposes that M cells mainly support E cells by cell-cell 
cooperation, and that epithelial metastases are directly 
derived from pre-existing E cells, implying that MICs 
are epithelial cells. Hence, metastasis would not require 
MET plasticity of individual M cells. Direct support for 
the cooperation metastasis model comes from reports that 
in mice coinjection of E and M cells increases distant 
metastasis formation derived from pre-existing E cells 
[6, 33, 34]. Thus, increased stemness and mammosphere 
formation of cooperating HMLER E and M cells, and of 
the mixed E/M state at the population level are consistent 
with the cooperation metastasis model [12]. The intriguing 
consequence of M cells being merely supporting cells 
for E MICs has not been examined in detail yet but 
would suggest that successful therapeutic induction of 
complete EMT beyond the intermediate E/M state might 
transdifferentiate epithelial cancers into a non-cancer 
M state, and possibly irreversibly eliminate E MICs. 
However, the cellular mechanism for how cooperation 
between E and M cells prevents detachment-induced 
anoikis and EMT plasticity of E cells remains unclear. 
To directly contrast the two metastasis models with 
either M or E cells being MICs, we combined in vitro and 
in silico strategies. In the in vitro studies using clonal E and 
M monocultures and E/M cocultures we studied whether 
upon detachment it is the M cells that underwent MET or 
the E cells that persisted and resisted detachment-induced 
anoikis, thereby initiating premetastatic E populations. To 
this end, we used the breast-derived heterogeneous basal 
HMLER cell line [29, 35], that contains both E (CD24+/
CD44–) and M (CD24–/CD44+) cell populations. Using 
publicly available breast cancer patient data, we compared 
the association of E versus M signatures with poor survival 
and metastases.
Together both our in vitro and patient data are in 
line with the cooperation metastasis model: we show in 
vitro that pre-existing E cells were required to generate E 
subpopulations and were supported by cooperation with 
transdifferentiated M cells. Consistently, in breast cancer 
patients, the expression of E signatures alone or together 
with M signatures predicted worse or equal outcomes than 
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pure M signatures, specifically for basal breast cancer 
patients, suggesting that E cells are the MICs. 
RESULTS
The suspension-induced intermediate E/M gene 
expression state is unstable in M cells upon 
readhesion, but stable in E cells
To form macrometastases cancer cells need to 
detach from the primary tumor, survive in suspension, 
and eventually readhere to a secondary site and express 
epithelial genes. To test the potential of M cells to 
undergo MET during the metastatic process, we used 
(bulk) mRNA expression profiling to assess the stability 
of the intermediate E/M state generated by M cells 
during suspension mammosphere culture, using the 
single cell-derived HMLER M clone M4, which only 
contained CD24–/CD44+ (M) cells but no CD24+/
CD44– (E) cells [12]. For comparison, and to test the 
alternative cooperation metastasis model with E cells 
as MICs, we tested the parental HMLER cell line (HP) 
containing mostly CD24+/CD44– E cells under the same 
conditions. As recently demonstrated, both HP and M4 
cells converged to the intermediate E/M state as assessed 
by gene expression analysis using 150 previously defined 
epithelial (E_HMLER) and mesenchymal (M_HMLER) 
specific gene sets [12] (Figure 1A). Since life-threatening 
metastases are epithelial and adherent we reasoned that 
replating to adhesion culture (Supplementary Figure 1A) 
should maintain at least some E signature expression and 
an intermediate E/M state. Surprisingly, already 24 hours 
following reattachment (and thereafter) the intermediate 
E/M mammosphere cultures derived from M4 cells had 
completely lost the E signature and regained pure M 
signature gene expression. This was suggestive of complete 
EMT of M4 cells upon readhesion back into an M state 
resembling that of the adherent source M cells from the 
M4 clone (Figure 1A). By contrast, replated HP-derived 
mammosphere cultures did not change gene expression 
pattern relative to that of the suspension cultures, and 
maintained their intermediate E/M state when analyzed at 
6 hours, 24 hours and even ten days past replating. 
To test the validity of these observations for other 
cell lines, we compared the gene expression profiles of 
adherent versus replated cultures of multiple HMLER 
M and E clones, as well as HP cells of different freezing 
passages. Gene expression profiles of these cells are 
visualized in a principal component analysis (PCA) 
that uses E and M signature gene expression values 
(Figure 1B). HMLER_E and HMLER_M signatures 
were originally defined by genes that discriminate most 
strongly between adherent HMLER E and M clones. The 
PCA placed adherent E and M clones to opposite ends of 
principal component 1 (PC1), while suspension cultures of 
either origin were located in the intermediate state between 
E and M states. Interestingly, in the PCA the M4 clones 
displayed a rapid, replating-induced reversion back to the 
Figure 1: Stability of the intermediate E/M state in epithelial but not in mesenchymal cell lines. (A) Heatmap of relative 
gene expression as measured in biological replicate arrays from HP and M4 cells that were grown in adhesion (adh), suspension as 
mammospheres (MS) and replated for the indicated times from 6 to 240 hours (re6, re24, re96, re240). Expression of indicated E_HMLER 
and M_HMLER (150) signatures are shown. (B) Principal component analysis (PCA) of gene expression arrays from M4 and HP cell 
lines in (A) and additional HP cell replicates, HMLER-derived E and M single cell clones cultured in adhesion and after replating using 
E_HMLER (150) and M_HMLER (150) signatures. Arrows in gray (HP) and blue (M4) indicate state changes of populations between 
adhesion, mammospheres and replating. All experiments shown were done in biological replicates (at least duplicates). 
Oncotarget20021www.oncotarget.com
original M state along PC1, suggesting complete EMT and 
instability of the M-derived E/M state in suspension. 
All additional M clones (M1, M2, M3, M5) exhibited 
the same trend and stably maintained their original M state 
with no increased E signature expression after replating 
(Figure 1B, Supplementary Figure 1B). As expected, 
suspension culture of E clones (E1 to E6) resulted in 
nearly no visible mammospheres compared to the M clones 
(Supplementary Figure 1A), consistent with anoikis of E 
cells [36] or quiescence upon detachment. Intriguingly, 
replating of each of the 6 tested E clone-derived cultures as 
well as each of the 11 mostly epithelial HP mammosphere 
cultures resulted in a viable readhesion culture that could 
be analyzed by gene expression analysis (Supplementary 
Figure 1A). In contrast to M clones, all biological replicates 
of 2 out of 3 tested E clones and all tested (epithelial) HP 
cell line replicates reached a stable intermediate E/M state 
due to partial loss of E signatures and gain of M signatures 
which is consistent with partial EMT after replating.
Taken together, these data suggested that HMLER 
M clones reside in a rather stable M state and the partial 
MET of M clones in suspension was only transient. By 
contrast, HMLER E cell lines consistently generated 
stable intermediate E/M populations upon suspension 
and replating. Thus, EMT was inevitable upon placing in 
suspension culture and replating of HMLER cells, which 
resulted in an increase of heterogeneity in E cell lines but 
loss of heterogeneity in M cell lines. 
Mesenchymal HMLER cell lines do not exhibit 
E/M heterogeneity when examined by single cell 
analysis
The population level gene expression data were 
consistent with our previous observations in single cell 
analyses of HMLER M clones that showed stable RNA 
expression of M signatures and absence of any E genes, 
while in HMLER E clones the majority cells individually 
co-expressed both E and M signatures indicating a hybrid 
E/M state [12]. To ensure that this finding was not due to 
potential clonal artifacts, we generated a lentiviral dual 
fluorescent reporter vector, designated CDH1 reporter, 
using the promoter for the gene CDH1, which encodes the 
epithelial adhesion protein E-Cadherin to drive expression 
of the red fluorescent mCherry (mCh) that reports the E 
state. The yellow fluorescence protein YFP expressed 
constitutively served as a positive control for presence of 
the reporter vector (Supplementary Figure 2A, Methods). 
As expected, CDH1 reporter-transduced mixed HP 
populations contained typical E colonies that co-expressed 
mCh and YFP, while cells classified as M cells based on 
morphology only expressed YFP (Figure 2A). Using FACS 
we then generated non-clonal trackable YFP-positive E and 
M cell lines by sorting for mCh+/YFP+ cells and mCh–/
YFP+ cells (Supplementary Figure 2B) corresponding 
to CD24+ epithelial E_YFP+ and CD24− mesenchymal 
M_YFP+ cell lines, respectively. As expected, all E_YFP+ 
and M_YFP+ cell lines resembled HMLER E and M 
clones, respectively, in CD24-expression (Figure 2B) and 
morphology (Supplementary Figure 2C). 
Next, we sorted individual YFP+ cells from the 
E_YFP+ and M_YFP+ cell lines passaged as adhesion 
cultures for single cell qPCR expression analysis of 9 
E-specific and 11 M-specific marker genes. Results were 
plotted in an E/M state space (Figure 2C) combining the 
cell state specific markers (Methods). qPCR analysis of 
E_YFP+ cells confirmed the previously observed E/M 
heterogeneity of E5 and non-clonal HP cell lines [12] 
since 11 of 19 evaluable E_YFP+ cells exhibited a hybrid 
E/M signature (58%), with four cells (21%) exclusively 
Figure 2: Abundance of hybrid E/M cells in E versus M HMLER cell lines. (A) Overlay fluorescent microscopy shows 
heterogeneous HP cells transduced with dual reporter construct (CDH1-reporter) where red indicates the E state by active CDH1 promoter 
visualized by mCherry and green indicates live and transduced cells by active SV40 promoter shown by YFP (40× magnification). (B) 
FACS profiles of αCD24-stained non-transduced and CDH1 reporter transduced stable E and M cell lines. (C) Single cell qPCR analysis 
shows E/M state space representation of E5, M4, E_YFP+, and M_YFP+ cell populations using aggregate expression of 9 E genes and 11 
M genes (see Methods). Note that E cell lines contain mostly hybrid E/M cells and M cell lines show complete EMT in most cells. Data 
are representative for both independent experiments using different reporter cell lines. 
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expressing M genes and four cells exclusively expressing 
E genes (Figure 2C). By contrast, only one (5%) of the 
20 evaluable single M_YFP+ cells showed a hybrid E/M 
signature, none expressed E genes, while all others (95%) 
exclusively expressed M genes, and thus resembled the 
M5 (Figure 2C) and M4 clones [12]. Thus, single cell 
analysis of nonclonal HMLER E and M reporter cell 
lines showed similarity with the respective clonal cell 
lines by sharing morphology, presence or absence of E/M 
heterogeneity, CD24 expression, and hybrid E/M status. 
Coculture with M cells allows for persistence of 
E cells during suspension culture and replating 
When subjected to suspension culture, HMLER 
E (CD24+/CD44–) populations either undergo anoikis 
or EMT and become CD24–/CD44+ (M) cells, while 
HMLER M (CD24–/CD44+) cells are not plastic and 
do not undergo MET [12]. Thus, it remains unclear how 
E cells can form macrometastases at a distant site after 
a prolonged detachment phase. To investigate whether 
cooperation between cells could be responsible for 
survival of E cells after suspension and replating, we 
examined cocultures of E and M HMLER cells. Using 
flow cytometry, E and M cells from a heterogeneous 
HMLER cell line were sorted and cocultured in a 1:1 ratio 
under suspension mammosphere conditions for two weeks. 
After dissociation of mammosphere cultures, staining, 
and flow cytometry, intriguingly we detected a small but 
consistently distinct CD24+/CD44– (E) subpopulation in 
these cocultures (Figure 3A). By contrast, no E cells but 
only pure M cell populations were detected when E or 
M cells were cultured by themselves (Figure 3A). Even 
increasing the seeded cell number from 2,000 to 16,000 
cells (Supplementary Figure 3A) did not induce an E cell 
subpopulation in the M clone-derived mammospheres, 
again suggesting the absence of spontaneous MET in M 
monocultures. Consistent with our previous findings of 
E and M cooperation [12], the 1:1 coculture resulted in 
increased total cell numbers compared to monoculture 
of E cells (more than 60-fold), M cells (more than 20-
fold), and more than 16-fold compared to HP cultures 
(Figure 3B). Replating suspension cultures to adhesion 
culture, staining, and flow cytometry analysis confirmed 
that the E population found in cocultures was stably 
maintained through the two weeks of each suspension 
culture and the subsequent replating, while it remained 
absent in replated mammospheres of E or M monocultures 
(Figure 3A, Supplementary Figure 3A). Intriguingly, 
in the heterogeneous HP cells that were mostly E cells 
(72%) but even under adhesion culture contained a 
pre-existing M subpopulation of 18%, we consistently 
detected an E subpopulation after suspension and replating 
(Supplementary Figure 3A) suggesting that cooperation 
could occur also in the mixed HP cell population. 
The presence of E cells in suspension cocultures, 
high E cell plasticity and absence of MET plasticity of 
M cells suggested that cooperation of E and M cells can 
facilitate survival, persistence, as well as readhesion of 
pre-existing E cells by cooperation with M cells indicating 
E cells being MICs. On the other hand, the findings could 
not exclude the possibility that coculture with E cells 
generates a suitable microenvironment for MET of M cells 
with M cells being MICs. 
Coculture of E and M cells results in persistence 
of E cells by suppression of epithelial plasticity
To identify whether E or M cells gave rise to the 
CD24+/CD44– (E) subpopulation under coculture 
conditions in suspension, we utilized the genetically YFP-
labelled E_YFP+ and M_YFP+ cell lines. Consistent with 
single cell analyses (Figure 2) and with observations in 
HMLER E clones and freshly sorted CD24+/CD44– (E) 
cells from HP cells (Figure 3A), E_YFP+ cells were 
highly plastic, as they converted to the CD24–/CD44+ 
(M) state after mammosphere suspension culture. Of 
note, during suspension-induced EMT E_YFP+ cells 
lost YFP expression. By contrast, within the same period 
of two weeks M_YFP+ cells retained YFP, and stably 
remained in their CD24−/CD44+ (M) state (Figure 3D) 
consistent with absence of plasticity in M clones. E and M 
cocultures were generated by sorting 1:1 ratios of E_YFP+ 
cells and M_YFP+ cells or in either combination with 
the non-fluorescent E5 and M5 clones under suspension 
mammosphere conditions (Figure 3C, 3D, Supplementary 
Figure 3B, 3C). According to our observations of 
cooperation (Figure 3A), all E and M cell coculture 
combinations consistently contained a small distinct 
E cell subpopulation and both E and M cells expressed 
YFP in dissociated suspension cultures (Figure 3D). 
Moreover, all combinations of E and M cell cocultures 
showed a synergistic increase of number of mammosphere 
formed (Figure 3C) and of cell numbers in dissociated 
mammosphere (Supplementary Figure 3B) by at least 
3-fold or 5-fold, respectively, relative to projected additive 
effect using numbers from E or M cell monocultures. 
Tracking the origin of E cells in cocultures of E_
YFP+ and unlabeled M5 cells exhibited an increased 
number of YFP+ mammospheres (5-fold) and YFP+/
CD24+/CD44− (E) cells (30-fold) compared to E_YFP+ 
suspension culture alone (Figure 3C, Supplementary 
Figure 3B). In these cultures, 83% of all E cells were found 
to express YFP (Figure 3D, Supplementary Figure 3C). 
Conversely, in mammosphere cocultures of M_YFP+ with 
E5 cells no E cells were YFP+ (Figure 3D, Supplementary 
Figure 3C). This suggested that during suspension 
mammosphere culture the E subpopulation was derived 
from pre-existing, persisting E cells and not by MET from 
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M cells, consistent with the hypothesis of an irreversibly 
transdifferentiated state of HMLER M cells. 
When tracking the origin of M cells in suspension 
in cocultures of M_YFP+ cells with E5 cells, we 
observed an increase of YFP+ mammospheres (3-fold) 
and of YFP+/CD24−/CD44+ cell (18-fold) numbers 
compared to M_YFP+ cells cultured alone (Figure 3C, 
Supplementary Figure 3B). Nearly all CD24−/CD44+ 
Figure 3: Coculture with M cells facilitates E cell persistence and inhibition of EMT in suspension. (A) After suspension 
mammosphere culture condition (MS), E cells are only found in mammospheres derived from E/M cell cocultures but not from E or M 
monocultures. Quantitative flow cytometry profiles of sorted E (CD24+/CD44−), M (CD24−/CD44+) subpopulations and unselected HP 
cells cultured alone or together (1,000 cells per cell-type) were grown as mammospheres for two weeks, and subsequently replated to 
adhesion for another week. (B) Total surviving cell numbers from dissociated mammosphere cultures shown in (A). (C) Total number of 
YFP- and YFP+ mammospheres per well after two weeks suspension of E/M cocultures and E or M monocultures as assessed by flow 
cytometry. (D) Flow cytometry analysis of dissociated and αCD24/αCD44-stained mammosphere cultures of E/M cell cocultures from 
(C) either gated for live cells (YFP+ and YFP−) or live YFP+ cells (YFP+) with each column representing the same sample. Note that no 
YFP+/CD24+/CD44− cells were found in E/M cocultures with M_YFP+ cells, and no YFP+/CD24−/CD44+ cells were detected in E/M 
cocultures with E-YFP+ cells. All data are representative for experiments performed in biological duplicates. 
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(M) cells were YFP+ in cocultures of E5 and M_YFP+ 
cells (97%). But surprisingly, no M cells were found to be 
YFP+ in cocultures of E_YFP+ and M5 cells (Figure 3C, 
Supplementary Figure 3C). Hence, the highly plastic 
E cells did not convert to the M state by EMT when 
cocultured in suspension with M cells. Together these data 
suggested that the mechanism of cooperation between E 
and M cells involves inhibition of E cell plasticity and is 
accompanied by proliferation of M cells. 
Besides the independent validation of absence of 
plasticity of HMLER M cells, cell tracking revealed that 
the increase of both E cells and M cells in suspension 
coculture of E and isogenic M cells is not a consequence 
of sequential EMT and MET at the single cell level but 
consistent with mutual E and M cell cooperation [37] 
which stimulated M cell expansion and persistence of E 
cells. 
Soluble factors and cell-cell contact mediate 
cooperation of E and M cells
We reasoned that this mutual cooperation in 
suspension of HMLER E and M cells could either be 
mediated by soluble paracrine factors released by the 
partner cell type or by direct cell-cell contact. Thus, we 
cultured E cell lines (E5 and HP cell lines with ~90% and 
~72% E cells in adhesion, respectively) and pure M cells 
in the presence of conditioned medium from adherent 
M4 cells (M4_cm) or from adherent E5 cells (E5_cm) 
(Figure 4A). Suspension culture of M4 cells with E5_cm 
led to an increase of total mammospheres and almost 
resembled the mammosphere increase observed by 
coculturing E and M cells. This suggested that soluble 
E factors can mediate the effect of coculture towards 
increased mammosphere formation and proliferation of 
M cells. By contrast, there was no stimulatory effect of 
M4_cm on mammosphere formation of E cells (neither in 
E5 nor HP cell lines) (Figure 4A). 
Consistently, cell-type analysis by CD24 and 
CD44 phenotyping of E or HP-derived mammospheres 
cocultured with the conditioned medium M4_cm showed 
no increase in E cell numbers (Figure 4B). As expected, 
no CD24+/CD44− E cells were found in dissociated 
mammospheres of M4 cells cultured with E5_cm or M4_
cm, again pointing to the absence of MET and the stably 
transdifferentiated state represented by the M clones. 
Thus, soluble paracrine E factors may be able to mediate 
the cooperation towards increased proliferation of M 
cells in suspension but do not induce MET, whereas no 
paracrine M cell factors could support persistence of E 
cells in suspension (Figure 4B). 
Next, we investigated cell-cell contact as possible 
mechanism for the cooperation through which M cells 
could confer persistence to E cells. While originally it 
had been proposed that mammospheres are clonal [38], 
more recently the picture that mammosphere actually 
can be aggregates of heterogeneous cell types has 
gained acceptance [39, 40]. If cell contact with M cells 
produced E cells persistence, we expected that E and M 
cells would form heterogeneous aggregates in suspension 
mammosphere cultures. To test this hypothesis, we 
transduced HP cells with a vector to constitutively express 
GFP (PCMV-YFP) or mCherry (PCMV-mCh), freshly sorted 
200 individual mCh+/CD24+/CD44− (E) cells together 
with 200 individual YFP+/CD24−/CD44+ (M) cells, 
and cocultured them under mammosphere conditions. 
We then imaged suspension cultures after two days. 
Indeed, we observed heterogeneous multicellular mCh+/
YFP+ aggregates (Figure 4C), suggesting that E and M 
cells exhibit affinity to each other even at very low cell 
densities and that aggregation with M cells may inhibit 
detachment-induced anoikis of E cells. 
M signatures predict more favorable patient 
outcomes than E signatures in basal breast cancer
Finally, we examined if recent findings in mouse 
models of M cells not being MICs [28, 28, 30, 31] and the 
HMLER cell tracking results presented here in support of 
the cooperation metastasis model are reflected in clinical 
data. Since metastasis is linked to poor patient survival our 
in vitro data would suggest that in patients the E signatures 
predict worse outcomes than M signatures. To test this 
hypothesis, we analyzed the predictive power of E and M 
signature expression for relapse free survival (RFS) and 
overall survival (OS) of up to 1764 or 626 breast tumor 
patients, respectively, by applying the Kaplan-Meier 
plotter (KMP) online tool [41, 42]. 
Using previously defined E- and M-specific HMLER-
derived gene expression signatures (Supplementary Figure 
4A, Supplementary Table 2, Methods) in the complete 
KMP breast cancer database, we found that the M_HMLER 
signature was significantly associated with favorable patient 
outcomes in terms of OS (HR = 0.7, p < 0.05) and RFS (HR 
= 0.74, p < 0.001). By contrast, the corresponding E gene set 
based on the E_HMLER signature predicted significantly 
poor outcomes (HR[OS]=1.88, HR[RFS]=1.81, p<0.0001) 
(Figure 5A). To ensure that these findings were due to 
particularities of the HMLER-specific gene sets, we rerun 
the analysis for four additional gene sets for the E and 
M signatures, derived independently from breast (Taube 
HMLE, Tan cell lines) and lung (Loboda) cancer cell lines 
[43, 49, 64] and different tumor types (Tan tumor) [49] 
(Methods and Supplementary Table 2). These alternative 
M gene signatures corroborated the above findings and 
indicated more favorable OS (between HR = 0.8 and 0.87) 
(Figure 5B), while the alternative E gene sets consistently 
predicted worse OS (between HR = 1.21 and HR = 1.52). 
However, the differences between the corresponding E and 
M signatures for these four additional E and M signature 
sets had overlapping 95% confidence intervals. Consistent 
with the reported stemness of the intermediate E/M state 
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[12] the combined presence of E and M signatures also 
predicted poor outcomes (between HR = 1.14 and HR = 
1.85, Figure 5B), resembling the outcome predicted by the 
E signatures. 
By induction of EMT in HMLE cell lines using 
siCDH1, SNAI1, TWIST, and GSC overexpression, 
or TGFβ treatment [43] Taube et al. had generated 
five different corresponding E and M signatures 
(Supplementary Table 2). An older KMP-database 
version significantly predicted favorable OS and RFS 
in breast cancer patients for these Taube M signatures 
alone (between HR = 0.58 and HR = 0.66, p < 0.017). 
Outcomes associated with M signatures were consistently 
better (between HR = 0.58 and HR = 0.63) than their 
corresponding E signatures alone (between HR = 0.76 
and HR = 1.4) or E signatures in combination with 
M signatures (between HR = 0.73 and HR = 0.88, 
Supplementary Figure 4C). Together, these observations 
are in agreement with the hypothesis of cooperation 
between E and M cells and of E cells being highly plastic 
and having potentially MIC character. 
To determine in which breast cancer subtype 
enrichment of the M signatures was associated with better 
outcomes and induction of complete EMT may possibly 
even have therapeutic benefit we used the St. Gallen 
criteria classification of the KMP and divided the tumors 
in the KMP database into the four canonical intrinsic 
subtypes: the ER-positive luminal A and luminal B tumor 
subtypes, the ER-negative basal and the HER2-positive 
subtypes [41, 44]. Intriguingly, in the basal breast cancer 
subtype we observed that all five M signatures consistently 
predicted more favorable outcomes (between HR = 0.36 
and HR = 0.72), while their corresponding E signatures 
predicted poor outcomes (between HR = 1.75 and HR = 
2.7). These differences between E and M signatures were 
significant within a 95% confidence interval for four out 
of the five signatures tested (Figure 5C). The same trend 
of E signatures predicting worse outcomes, albeit not 
within 95% intervals, was observed for the five different 
Figure 4: The role of soluble factors and direct cell-cell contact for synergistic effect of E/M coculture in suspension. 
(A) Relative numbers of mammospheres from HP, E5 or M4 clone cells after treatment with conditioned medium (CM) of adherent E or 
M cells or E/M coculture. Average of data performed in duplicates is shown. (B) Quantitative flow cytometry of the four different CD24/
CD44 subpopulations from (i) in adhesion grown source cells and from (ii) cells found in dissociated mammospheres after mono- and 
coculture of E and M cells with or without CM. (C) Spontaneous heterogeneous aggregates of freshly sorted CMV-driven mCherry-
labelled CD24−/CD44+ (M) and CMV-driven GFP-labelled CD24+/CD44− (E) cells after 2 days culture under mammosphere conditions.
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Taube EMT signatures in the basal subtype in an older 
database (Supplementary Figure 4C). In none of the 
other breast cancer subtypes was a consistent difference 
for outcomes between tumors with predominant E and 
M signatures observed (Figure 5C); in the luminal A 
and B subtypes both E and M signatures were associated 
with poor OS, while in the HER2+ subtype four of the 
five tested E signatures (between HR = 1.67 and HR = 
2.1) were also associated with worse outcomes than M 
signatures (between HR = 0.33 and HR = 0.75), which 
was significant within a 95% confidence interval for two 
of the five tested E and M signature pairs. 
In conclusion, patient data show that E signatures 
are mostly associated with worse outcome than M 
signatures in breast cancer, thus supporting the hypothesis 
that E cells rather than M cells represent the MICs in 
breast cancer, particularly in basal breast cancer.
DISCUSSION
Most life-threatening macrometastases in breast 
cancer are epithelial and resemble the primary tumors. 
However, it is still unclear how anoikis-prone E cells 
reach distant metastatic sites after detachment, and 
whether M or E represent the MICs that give rise to the 
E metastases. Using the basal-like breast cancer cell 
line HMLER, we present here in vitro evidence that 
MICs may originate from cells in the epithelial state 
and that mutual cooperation with M cells can support 
the survival and persistence of a pre-existing CD24+/
Figure 5: M signatures indicate more favorable patient outcomes than E signatures in basal breast cancer. (A) Kaplan 
Meier plots for RFS and OS associated with HMLER_E and HMLER_M signatures in breast cancer. Patient numbers, hazard ratio (HR), 
95% confidence intervals, and logrank p-values (P) for respective signatures are indicated. (B) HR for OS associated with E, M and E/M 
composite signatures derived from different sources in breast cancer (626 patients). Asterisks indicate signatures predicting OS with p 
values < 0.05. (C) HR for OS associated with different E and M signatures in different breast cancer subtypes. Analyzed patient numbers 
are indicated in brackets.
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CD44– (E) subpopulation and lead to E cell proliferation 
in suspension culture. We further provide evidence 
that M cells can reside in the stable (irreversible) M 
transdifferentiated state such that they are unlikely to 
undergo MET but rather function to aid in stabilizing the 
E population by suppressing their anoikis and plasticity, 
i.e., their inherent potential to undergo EMT. Thus, our 
data are consistent with a series of recent mouse studies 
demonstrating that M cells do not give rise to metastasis 
by MET [6, 30, 31, 33, 34]. Consistent with our in vitro 
data, clinical data show that M signatures predict better 
outcomes in breast cancer patients than E signatures, 
particularly in basal breast tumors. Together, these data 
support the cooperation metastasis model in which E cells 
are the MICs. 
In our previous study we had determined that 
stemness was associated with the intermediate E/M state 
for most breast cancer subtypes as well as for the HMLER 
E and M cell lines. However, it remained unclear whether 
stemness depended upon individual stem-like hybrid E/M 
cells or on the mixture of M and E cells which would 
suggest E-M cooperation [12]. By analyzing individual 
clonal E and M populations alone as well as E and M 
mixtures, and reporter cell lines, our present data suggest 
the existence of two different types of hybrid E/M cells: 
(i) hybrid E/M cells derived from M cells which were 
instable and underwent EMT when allowed to readhere, 
and (ii) hybrid E/M cells derived from E cells which were 
stable and found in the majority of tested E population 
(Figure 2C). These observations reinforced our previous 
notion that HMLER E cells display much more plasticity 
along the E-M axis than M cells, and that E cells are more 
likely to give rise to heterogeneous E and M signatures in 
HMLER cell populations with stemness properties [12]. 
We conclude that at least in HMLER cells mainly E cells 
have the potential to give rise to cooperating E and M 
populations. If that holds true for breast cancer in general, 
then pre-existing and residual E cells from the original 
tumor would be necessary to produce at a metastatic site 
the same epithelial heterogeneity as in the primary tumor. 
The observation that in breast cancer patients in general, 
and particularly in the basal subtypes, better survival 
correlates with M signatures supports this notion, and 
is in agreement with findings of other reports that used 
different and smaller databases [43, 49]. 
Our results on the absence of complete MET at the 
single cell level in HMLER cells stand in sharp contrast 
to the popular assumption that metastasis is caused by 
cellular plasticity of individual highly aggressive cancer 
stem cells [13, 45] that undergo EMT, thereby generating 
more aggressive cell types [4, 5]. According to this 
perspective, M cells resulting from EMT are considered 
the MICs and will have to eventually undergo MET, in 
accordance to the sequential metastasis model [17, 46]. 
Our results suggest that pre-existing E cells acting as 
MICs, generate the adherent E population after replating 
following a suspension phase and represent the majority of 
cells in our HMLER model; however, we cannot exclude 
the occasional existence of M MICs and of spontaneous 
METs that may be triggered by rare mutations. In 
support of our findings, we observed that EMT was 
nearly inevitable for individual E HMLER cells once 
detached from the adhesion state, which may also apply 
to metastatic E cells leaving the primary tumor (Figures 1, 
2). Furthermore, EMT even occurred in M clones that had 
transiently undergone a partial MET (Figure 1B). Thus, 
any spontaneous partial MET would be overridden by the 
default EMT process upon detachment and readhesion. 
Finally, although our data suggest that MET at the single 
cell level may be unlikely, the migratory and less adherent 
nature of M cells in proliferating mixed populations 
may lead to an enrichment of E cells and an apparent 
(population level) MET in certain metastatic solid tumors. 
A few but important experimental differences to 
earlier studies [4, 13, 45] may underlie the discrepancy 
between previous reports and our results. First, we have 
not only used a single cell line but a series of single cell-
derived clones as well as stable reporter cell lines, which 
has enabled us to identify the individual E and M cell 
fate (Figure 1B). Second, previous studies [4, 5, 45] used 
mixed E and M populations for sorting. However, mixed 
cell populations (as shown for HMLER cells) may still 
contain two types of CD24−/CD44+ (M) cells, pure M 
cells originated from completed EMT, as well as stem-
like hybrid E/M cells which may have been directly and 
recently derived from the highly plastic E cells [12]. To 
overcome this bias, we used here clonal populations or 
stable M reporter cell lines that had undergone complete 
EMT and only contained pure M cells as determined 
by single cell analysis (Figure 2C). Third, to track cell 
fates we cultured cells under suspension mammosphere 
conditions that allowed nearly clonal expansion that 
mimic the metastatic process that is thought to start 
from few cells. By contrast in other studies [4, 5, 45] 
large numbers of E versus M cells were sorted directly 
into highly charged 2D adhesion plastic dishes which 
favors an apicobasal polarity and adhesion as is needed 
for the E phenotype, potentially preventing complete 
EMT of “contaminating” E cells. Along the same lines, 
it has been suspected that 2D adhesion cultures do not 
accurately replicate cancer cell behavior in patients, and 
that 3D or mammosphere suspension cultures better reflect 
tumor heterogeneity [38, 47, 48]. Thus, the controversial 
experimental results may be explained by our experimental 
conditions that model metastasis by detachment of 
tumor cells, a prolonged suspension culture phase, and 
readhesion as opposed to experimental conditions that 
relied on cells exclusively cultured in adhesion. 
Given that we did not observe plasticity in the sense 
of MET in vitro, dominance of EMT upon detachment 
and readhesion as well as the significant association 
of M signatures with favorable patient survival in 
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basal tumors, it could be assumed that complete EMT 
in individual breast-derived cells may represent an 
irreversible transdifferentiation into a non-tumorigenic 
state and associated tumor microenvironment, as opposed 
to a reversible transition into aggressive cells. The 
tendency of the epithelial HMLER cell lines to undergo 
transdifferentiation towards the M state upon detachment 
may thus explain their low tumorigenicity and absence 
of metastasis in mouse models [49]. Even upon normal 
passaging for more than 15 passages, HMLER cells tended 
to spontaneously undergo EMT (Supplementary Figure 1A), 
and thus EMT of E populations and tumors may be 
inevitable during development. Indeed, a combination 
of experimental data and mathematical modelling 
demonstrated that e.g. the transcription factor GRHL2 
stabilizes the intermediate E/M state and predicts poor 
outcomes in breast, kidney, lung, and liver cancers [50]. 
Mechanistically, we present evidence at the cellular 
level that cooperation is not mainly mediated by soluble 
factors but also by direct cell-cell contact of pre-existing 
HMLER E cells and stably transdifferentiated M cells 
(Figure 4C). Thus direct E-M cell contact may prevent 
EMT of E cells. This is in contrast to studies showing 
that mammospheres are clonal [38], but consistent with 
several recent studies demonstrating non-clonality of 
mammospheres [40]. Our results are also in agreement 
with observations that circulating tumor cell (CTC) 
clusters are substantially more tumorigenic than individual 
CTCs [51], and that fresh patient-derived tumors are best 
propagated in mice as clusters. More studies are needed to 
understand if E and M cell clustering can prevent EMT in 
primary tumors, and which molecular mechanisms mediate 
the clustering. Furthermore, our data on cooperation of E 
cells with the transdifferentiated M cells support studies 
suggesting that clustering with stromal cells of the tumor 
microenvironment, such as mesenchymal stem cells [52, 
53] or fibroblasts [54, 55] can promote outgrowth of 
metastatic breast cancer cells.
MATERIALS AND METHODS 
Cell culture 
HMLER cells are primary human mammary 
epithelial cells (HMECs) transformed to carcinoma 
cells through the introduction of SV40 large T and Ras 
oncogene [35]. HMLER cells were kindly provided 
by Robert A. Weinberg (Whitehead Institute). Parental 
HMLER (HP) cells, single cell-derived epithelial (E1 
to E6) and mesenchymal HMLER clones (M1 to M5) 
were described previously [12]. All HMLER-derived cell 
lines were passaged in adhesion under serum-free culture 
conditions in a 1:1 mix DMEM (Life Technologies)/
MEGM (Lonza). Conditioned medium (CM) was 
harvested from adherent nearly confluent E5 and M4 cells 
and separated from suspended cells by centrifugation.
Mammospheres (MS) were generated as described 
earlier [38]. Briefly, adherent cells were trypsinized, and 
(unless otherwise stated) cell numbers of 10,000 to 20,000 
cells/ml were either flow cytometry-sorted or pipetted into 
ultra-low attachment (ULA) plates (96 well plates, 100ul 
volume, Corning). Mammospheres were cultured for 2–3 
weeks in DMEM/MEGM supplemented with 1× B27 
(Life Technologies) and 1% methylcellulose (viscosity 
4,000cP, Sigma) in biological duplicates. E/M cocultures 
were always generated from equal numbers of E and M 
cells, and compared to equal total numbers of E or M 
monocultured cells. Mammospheres were counted by eye 
with a 4x or 10x objective. For replating mammospheres 
to adhesion cultures, 50% of dissociated non-stained 
mammosphere suspension cultures was transferred into 
normal adhesion culture conditions and analyzed by 
quantitative flow cytometry after one week. For gene 
expression arrays replated cultures were analyzed after 6 
hours to 10 days (for HP cells and M clones) and after 2–3 
weeks (E clones) as indicated in the text. 
Sorting and single cell qPCR analysis
Single cell analysis was performed as described 
before [12]. Briefly, live single cells of equal FSC/
SSC morphologies within the middle of the respective 
fluorescent gates were sorted directly into 96 well-plates. 
Wells contained Taqman primers and Cells Direct One-step 
RT-PCR and pre-amplification mix (Life Technologies) 
followed by RT and 18 cycles of preamplification in 
a GeneAmp PCR System 9700 instrument (Applied 
Biosystems) according to the Fluidigm single cell protocol. 
Gene expression was analyzed on a BioMark instrument 
using 48.48 Dynamic Array IFC chips (Fluidigm) and 
Taqman primers (Applied Biosystems). 
Single cell data were analyzed similar as described 
previously [12]. Briefly, measured Ct values were 
transformed into linear expression values according to 
Fluidigm’s single cell application protocol. Expression 
data for every E gene was normalized to the value of the 
maximum measured for the same gene in a simultaneously 
analyzed 100-cell samples of adherent E cells (HP and E4 
cells) and divided by 100, while M genes were normalized 
for maximum measured 100-cell value in adherent M5 
cells. To plot single cell gene expression values into the 
E/M state space, normalized expression values per single 
cell were averaged for 9 E genes (CDH1, EPCAM, KRT5, 
LCN2, S100A8, S100P, SLPI, TP63, TNFSF10/TRAIL) 
and 11 M genes (ABCA6, AR, CDH2, DCN, FN1, 
PCOLCE, SNAI1, VIM, WNT5A, ZEB1, ZEB2). 
Gene expression arrays and principal component 
analysis 
RNA of cells grown in adhesion was isolated 
by lysing PBS-washed cells by addition of Trizol (Life 
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Technologies) to the adherent cells in the dish, as 
detaching of cells before Trizol resulted in substantial 
RNA degradation. RNA was purified according to the 
manufacturer’s instructions. Gene expression analysis 
was performed essentially as described [12]. Briefly, 
50 ng to 100 ng RNA was labeled using the one color 
Low Input Quick Amp Labeling Kit (Agilent), and 
labeled probes were run on Human 4 × 44 K Microarrays 
(Agilent) according to the manufacturer’s instructions. 
Data were analyzed with Genedata Analyst 7.0 (Genedata, 
Basel, Switzerland). Data normalization was performed 
using central tendency followed by relative normalization. 
Principal Component Analysis (PCA) of gene expression 
array data was performed using the indicated 150 most E- 
and M-specific signatures by using a covariance matrix in 
GeneData Analyst 7.0. 
The complete microarray dataset shown in Figure 1 
has been deposited in NCBI’s Gene Expression Omnibus 
and is accessible through GEO accession numbers 
GSE66527 (adherent cells and mammospheres) and 
GSE70279 (replated cells). RNA of adhesion cultures was 
derived from five different freezing passages of HP cells, 
five HMLER M clones and six different HMLER E clones 
(biological duplicates). RNA of readhesion cultures was 
derived from HP cells (10 biological replicates from four 
different passages), and three different E clones and M 
clones (biological duplicates). 
Staining and flow cytometry analysis
Single cell suspensions of trypsinized adherent 
growing cells or dissociated mammospheres were stained 
with antibodies (αCD24-PE: clone ML5, αCD44-FITC 
or αCD44-APC: clone G44–26, BD-Biosciences) diluted 
1:25 in DMEM supplemented with 2% FBS and 25 mM 
HEPES. Flow cytometry data acquisition was performed 
on a FACSAria II SORP (Becton Dickinson) and analyzed 
with FlowJo software (Tree Star, vX.0.6). To determine 
cutoffs for the CD24/CD44 quadrants for any cell line, 
simultaneously stained heterogeneous HP cells (expanded 
in adhesion) were included as a reference. Relative cell 
numbers in mammosphere cultures within an experiment 
were determined by ‘quantitative flow cytometry’ 
assessing cell numbers in the same volumes and same 
time. All data shown are representative of at least two 
experiments performed in biological replicates. 
Generation of fluorescent E and M reporter cell 
lines
For tracking origin of E and M cells, we generated 
a lentiviral dual fluorescent CDH1-promoter reporter 
vector (pLenti6-PCDH1-mCherry_PSV40-YFP). The 8.6kb 
long CDH1-promoter reporter vector could track CDH1 
transcriptional activation by driving fluorescent mCherry 
expression and simultaneously showed presence of 
the promoter reporter construct itself by using the 
constitutively active SV40 promoter driving expression of 
yellow fluorescent protein (YFP). Using the commercially 
available pLenti6/V5-D-TOPO vector (Thermo Fisher) 
as a base, we exchanged the CMV promoter with the 
human CDH1 promoter (PCDH1). A sequence of 1122 bp 
of the human CDH1 promoter region (-1178 through -57 
upstream of the initiator methionine) was PCR amplified 
using 293T cell genomic DNA using the forward primer 
(5′ agatcagcctcggcaacatagtg 3′) and reverse primer (5′ 
gctggagcgggctggagtctga 3′). The CDH1 promoter drives 
the expression of a 711 bp mCherry open reading frame 
[60]. The blasticidin ORF of the original vector pLenti6/
V5-D-TOPO was replaced by the 720 bp long YFP ORF 
[61], so that YFP is constitutively expressed by the PSV40 
promoter of the original vector. 
Transduction of heterogeneous HP cells was 
performed using the Virapower Lentiviral Expression 
Systems kit (Life Technologies). Briefly, the CDH1-
mCherry reporter construct together with pLP1, pLP2, 
and pLP/VSVG was transfected into 293FT cells. HP 
cells were then transduced with the virus-containing 
supernatant, expanded, and after cell sorting the two 
YFP-positive cell lines (mCherry-positive E_YFP+ and 
mCherry-negative M_YFP+) were derived and expanded. 
Single cell qPCR data (Figure 2) and cytometry data 
(Figure 3) shown are representative for two independently 
derived E_YFP+ and M_YFP+ cell lines. 
Microscopy
Cells were imaged on a DM IL LED instrument 
(Leica) with a DFC345 FX camera or on a DeltaVision 
Core instrument (GE Healthcare). 
Kaplan-Meier survival analysis 
The ‘Kaplan-Meier Plotter’ (KMP) online tool 
(kmplot.com) was used with either the 2017 breast 
cancer dataset (1764 and 626 patients for ‘relapse-free 
survival’ (RFS) and ‘overall survival’ (OS), respectively). 
According to the KMP tool breast cancer (all BC subtypes) 
is classified into four clinically relevant intrinsic subtypes 
based on the St. Gallen criteria using bimodal expression 
of estrogen receptor (ER, ESR), expression of HER2 
(HER2), and the proliferation marker Ki67 (MKI67) 
into luminal A (ESR+, HER2-, MKI67low), luminal B 
(ESR+,HER2-, MKI67high and ESR+, HER2+), basal 
(ESR-, HER2-) and HER2+ (ESR-, HER2+) patients 
[41, 42]. Hazard ratio (‘HR’, within 95% confidence 
intervals) and logrank p-values (Cox’ proportional hazard 
ratio analysis) for survival of breast cancer patients 
[41] was determined by the mean expression of the 
respective gene signatures (Supplementary Tables 1 and 2) 
[12, 43, 62, 63]. The ‘autoselect best cutoff’ option [64] was 
used for subdividing gene expression in primary tumors by 
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median, quartile or tertile expression, and ‘JetSet best probe 
set’ [44] option was used to assess HR, 95% confidence 
intervals and logrank p-values for patient survival. 
Gene signatures
All E and M gene signatures were derived by 
comparing epithelial versus mesenchymal cell lines 
cultured in vitro or in mice, and contained the 24 
(Supplementary Table 1), 50 (Supplementary Table 2) or 
150 [12] most differentially expressed genes. E_HMLER 
and M_HMLER signatures were defined from HMLER E 
and M clones as described before [12]. The Taube HMLE 
E and M signatures were derived from HMLE cells 
induced to undergo EMT by transduction with siCDH1, 
SNAI1, TWIST, GSC, or treatment with TGFβ, or from 
the overlap respective overlap (Taube HMLE) [43]. E_
Tan and M_Tan signatures were based on breast cancer 
cell lines or tumors [63], and E_Loboda and M_Loboda 
signatures were derived from lung tumors [62]. 
CONCLUSIONS
To our knowledge the intriguing consequence of 
complete EMT  irreversibly converting E to M cells, hence 
eliminating MICs has not been explored yet. It is generally 
assumed that tumors become gradually more aggressive 
over time accumulating conversion into M cells. Hence, 
much effort went into exploring the inhibition of EMT and 
inducing MET as a therapeutic strategy [56, 57]. This may 
be detrimental in view of the findings presented here where 
enrichment for M signatures are associated with better 
outcomes and E signatures with worse outcomes in breast 
cancer. It is noteworthy that basal tumors are considered 
more mesenchymal tumors than luminal tumors. In support 
of the new notion that the M state is less aggressive, 
and thus, that EMT does not necessarily result in more 
aggressive tumors, basal breast cancer patients have a 
indeed a higher pathological response rate and better long 
term survival than luminal breast cancer patients, albeit 
worse short term outcomes [58, 59]. 
Our in vitro and patient analysis suggest that tumor-
specific therapeutic induction of complete EMT may have 
a long lasting clinical benefit in basal (triple-negative) 
breast cancer patients due to a potential irreversibility of 
EMT of individual cells and corresponding inhibition of 
epithelial metastases. Particularly patients with basal ER-
negative breast tumors have an unmet clinical need due to 
absence of targeted therapies for this subtype. Given that 
M signatures are associated with favorable outcomes these 
patients may benefit from EMT induction. 
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